GNE-317
featured

We will be closed during Nov. 25-28 for observance of thanksgiving. Orders received during Nov 24-28 will be shipped on Nov 29

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406637

CAS#: 1394076-92-6

Description: GNE-317 is a potent and selective PI3K inhibitor with potential anticncer activity. GNE-317 targets the PI3K pathway and can cross the Blood–Brain Barrier. GNE-317 was identified as having physicochemical properties predictive of low efflux by P-gp and BCRP. Studies in transfected MDCK cells showed that GNE-317 was not a substrate of either transporter. GNE-317 markedly inhibited the PI3K pathway in mouse brain, causing 40% to 90% suppression of the pAkt and pS6 signals up to 6-hour postdose.


Chemical Structure

img
GNE-317
CAS# 1394076-92-6

Theoretical Analysis

MedKoo Cat#: 406637
Name: GNE-317
CAS#: 1394076-92-6
Chemical Formula: C19H22N6O3S
Exact Mass: 414.1474
Molecular Weight: 414.48
Elemental Analysis: C, 55.06; H, 5.35; N, 20.28; O, 11.58; S, 7.73

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 Ready to ship
50.0mg USD 250.0 Ready to ship
100.0mg USD 450.0 Ready to ship
200.0mg USD 750.0 Ready to ship
500.0mg USD 1650.0 Ready to ship
1.0g USD 2850.0 Ready to ship
2.0g USD 4750.0 2 Weeks
5.0g USD 6950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: GNE317; GNE 317; GNE-317.

IUPAC/Chemical Name: 5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine

InChi Key: XOZLHJMDLKDZAL-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H22N6O3S/c1-11-13-14(29-15(11)19(26-2)9-28-10-19)17(25-3-5-27-6-4-25)24-16(23-13)12-7-21-18(20)22-8-12/h7-8H,3-6,9-10H2,1-2H3,(H2,20,21,22)

SMILES Code: NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(C5(OC)COC5)S4)=N2)C=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: GNE-317 is a potent, brain-penetrant PI3K inhibitor.
In vitro activity: The bidirectional transport of GNE-317 was assessed in transfected cell lines overexpressing human or mouse P-gp or BCRP. The apparent permeability (Papp) was high and comparable to that determined for metoprolol, the high Papp marker used in the same experiments (data not shown). The ERs (Papp, B-A/Papp, A-B) were not markedly different from 1 in the MDCK or LLC-PK1 transfected cells (Table 1), indicating that GNE-317 was not impacted by the overexpression of the human or mouse P-gp and BCRP, and suggesting that this compound was a poor substrate of these transporters. Reference: Clin Cancer Res. 2012 Nov 15;18(22):6239-48. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=22992516
In vivo activity: The efficacy of GNE-317 was tested in 3 intracranial tumor models, the U87, the neurosphere GS2 and the GBM10 models. GNE-317 was administered PO at 40 mg/kg daily for 3 and 6 weeks to U87 and GS2 tumor-bearing mice, respectively, and for more than 12 weeks to GBM10 tumor-bearing mice. The effect of the treatment on the U87 and GS2 tumor volumes was assessed at the end of the dosing period. A U87 tumor image obtained by micro-CT is presented in Fig. 2C. GNE-317 reduced the U87 tumor volumes by more than 90%, when compared with the vehicle control (Fig. 2D). Bioluminescence measured before and at the end of treatment (Supplementary Table 1) displayed halted tumor growth with GNE-317, which was consistent with in vitro findings that showed cytostasis (Supplementary Fig. 2) but no cell death. Similarly, the GS2 tumors measured by MRI (Fig. 2A) in the treated mice were more than 50% smaller than those in the control group (Fig. 2B). GDC-0941, a PI3K inhibitor that does not cross the BBB (16), was also tested in these 2 models. In contrast to GNE-317, GDC-0941 showed no activity in the GS2 model (Fig. 2A and B), whereas it was able to reduce the U87 tumor volumes by 66% (Fig. 2C and D). To assess whether the absence of efficacy of GDC-0941 was related to its lack of mTOR inhibition, the dual PI3K/mTOR inhibitor GDC-0980 (17, 18) was also tested in the GS2 model. GDC-0980 is a substrate of P-gp and bcrp1 (19). Similarly to GDC-0941, GDC-0980 showed no activity against the GS2 model (Fig. 2A and B). Plasma and brain concentrations and brain-to-plasma ratios determined at the end of the study in the GS2 tumor-bearing mice are presented in Supplementary Table 2. For the 3 compounds, the brain concentrations and brain-to-plasma ratios were comparable in the normal part of the brain and in the tumored brain. In the GBM10 model, GNE-317 was able to extend the survival of mice from a median of 55.5 to 75 days (P < 0.05, log rank test; Fig. 2E) when administered at 30 mg/kg (40 mg/kg the first 2 weeks). Reference: Clin Cancer Res. 2012 Nov 15;18(22):6239-48. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=22992516

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 20.0 48.3

Preparing Stock Solutions

The following data is based on the product molecular weight 414.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
In vitro protocol: 1. Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19. PMID: 22992516. 2. Salphati L, Shahidi-Latham S, Quiason C, Barck K, Nishimura M, Alicke B, Pang J, Carano RA, Olivero AG, Phillips HS. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014 Jul;42(7):1110-6. doi: 10.1124/dmd.114.057513. Epub 2014 Apr 22. PMID: 24754926.
In vivo protocol: 1. Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19. PMID: 22992516. 2. Salphati L, Shahidi-Latham S, Quiason C, Barck K, Nishimura M, Alicke B, Pang J, Carano RA, Olivero AG, Phillips HS. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014 Jul;42(7):1110-6. doi: 10.1124/dmd.114.057513. Epub 2014 Apr 22. PMID: 24754926.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Salphati L, Shahidi-Latham S, Quiason C, Barck K, Nishimura M, Alicke B, Pang J, Carano RA, Olivero AG, Phillips HS. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014 Jul;42(7):1110-6. doi: 10.1124/dmd.114.057513. Epub 2014 Apr 22. PubMed PMID: 24754926.

2: Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19. PubMed PMID: 22992516.

GNE-317

25.0mg / USD 150.0


Additional Information